Phase II study of weekly amrubicin for refractory or relapsed non-small cell lung cancer

Chiyoe Kitagawa; Masahiro Iwasaku; Yoshihito Kogure; Masahiko Ando; Hiroshige Yoshioka; Akihiro Nishiyama; Naoki Watanabe; Kei Kunimasa; Kazuya Tsubouchi; Saori Oka; Hideo Saka

doi:10.21873/invivo.11453

Phase II study of weekly amrubicin for refractory or relapsed non-small cell lung cancer

Chiyoe Kitagawa, Masahiro Iwasaku, Yoshihito Kogure, Masahiko Ando, Hiroshige Yoshioka, Akihiro Nishiyama, Naoki Watanabe, Kei Kunimasa, Kazuya Tsubouchi, Saori Oka, Hideo Saka

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Background: Amrubicin is usually administered on days 1-3 every 3 weeks by intravenous infusion. However, it causes severe hematological toxicity, especially febrile neutropenia. It was reported that weekly administration confers higher dose intensity, less severe adverse events, and anti-tumor activity that is as effective as that of treatment with a conventional schedule. Patients and Methods: Weekly amrubicin was administered at a dose of 60 mg/m² on days 1 and 8 every 3 weeks. The primary endpoint was overall response rate. Results: A total of 33 patients were enrolled. The overall response rate was 6.1% (95% confidence interval(CI)=0.7-20.2%) and the disease control rate after 2 months was 51.5%. The median progression-free survival was 2.93 months. Febrile neutropenia was observed in only two patients. Conclusion: The primary endpoint was not met in this study. However, weekly amrubicin achieved a high disease control rate and good tolerability.

Original language	English
Pages (from-to)	163-166
Number of pages	4
Journal	In Vivo
Volume	33
Issue number	1
DOIs	https://doi.org/10.21873/invivo.11453
Publication status	Published - 01-01-2019
Externally published	Yes

All Science Journal Classification (ASJC) codes

General Biochemistry,Genetics and Molecular Biology
Pharmacology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/invivo.11453

Cite this

@article{5890d1f6b2c241cbaeefe76010c99128,

title = "Phase II study of weekly amrubicin for refractory or relapsed non-small cell lung cancer",

abstract = "Background: Amrubicin is usually administered on days 1-3 every 3 weeks by intravenous infusion. However, it causes severe hematological toxicity, especially febrile neutropenia. It was reported that weekly administration confers higher dose intensity, less severe adverse events, and anti-tumor activity that is as effective as that of treatment with a conventional schedule. Patients and Methods: Weekly amrubicin was administered at a dose of 60 mg/m2 on days 1 and 8 every 3 weeks. The primary endpoint was overall response rate. Results: A total of 33 patients were enrolled. The overall response rate was 6.1% (95% confidence interval(CI)=0.7-20.2%) and the disease control rate after 2 months was 51.5%. The median progression-free survival was 2.93 months. Febrile neutropenia was observed in only two patients. Conclusion: The primary endpoint was not met in this study. However, weekly amrubicin achieved a high disease control rate and good tolerability.",

keywords = "Amrubicin, Non-small cell lung cancer, Phase II, Refractory, Relapsed",

author = "Chiyoe Kitagawa and Masahiro Iwasaku and Yoshihito Kogure and Masahiko Ando and Hiroshige Yoshioka and Akihiro Nishiyama and Naoki Watanabe and Kei Kunimasa and Kazuya Tsubouchi and Saori Oka and Hideo Saka",

year = "2019",

month = jan,

day = "1",

doi = "10.21873/invivo.11453",

language = "English",

volume = "33",

pages = "163--166",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "1",

}

TY - JOUR

T1 - Phase II study of weekly amrubicin for refractory or relapsed non-small cell lung cancer

AU - Kitagawa, Chiyoe

AU - Iwasaku, Masahiro

AU - Kogure, Yoshihito

AU - Ando, Masahiko

AU - Yoshioka, Hiroshige

AU - Nishiyama, Akihiro

AU - Watanabe, Naoki

AU - Kunimasa, Kei

AU - Tsubouchi, Kazuya

AU - Oka, Saori

AU - Saka, Hideo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Amrubicin is usually administered on days 1-3 every 3 weeks by intravenous infusion. However, it causes severe hematological toxicity, especially febrile neutropenia. It was reported that weekly administration confers higher dose intensity, less severe adverse events, and anti-tumor activity that is as effective as that of treatment with a conventional schedule. Patients and Methods: Weekly amrubicin was administered at a dose of 60 mg/m2 on days 1 and 8 every 3 weeks. The primary endpoint was overall response rate. Results: A total of 33 patients were enrolled. The overall response rate was 6.1% (95% confidence interval(CI)=0.7-20.2%) and the disease control rate after 2 months was 51.5%. The median progression-free survival was 2.93 months. Febrile neutropenia was observed in only two patients. Conclusion: The primary endpoint was not met in this study. However, weekly amrubicin achieved a high disease control rate and good tolerability.

AB - Background: Amrubicin is usually administered on days 1-3 every 3 weeks by intravenous infusion. However, it causes severe hematological toxicity, especially febrile neutropenia. It was reported that weekly administration confers higher dose intensity, less severe adverse events, and anti-tumor activity that is as effective as that of treatment with a conventional schedule. Patients and Methods: Weekly amrubicin was administered at a dose of 60 mg/m2 on days 1 and 8 every 3 weeks. The primary endpoint was overall response rate. Results: A total of 33 patients were enrolled. The overall response rate was 6.1% (95% confidence interval(CI)=0.7-20.2%) and the disease control rate after 2 months was 51.5%. The median progression-free survival was 2.93 months. Febrile neutropenia was observed in only two patients. Conclusion: The primary endpoint was not met in this study. However, weekly amrubicin achieved a high disease control rate and good tolerability.

KW - Amrubicin

KW - Non-small cell lung cancer

KW - Phase II

KW - Refractory

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=85059225879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059225879&partnerID=8YFLogxK

U2 - 10.21873/invivo.11453

DO - 10.21873/invivo.11453

M3 - Article

C2 - 30587617

AN - SCOPUS:85059225879

SN - 0258-851X

VL - 33

SP - 163

EP - 166

JO - In Vivo

JF - In Vivo

IS - 1

ER -

Phase II study of weekly amrubicin for refractory or relapsed non-small cell lung cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this